Key takeaways:
-
EuroHeartPath aims to transform cardiovascular care across Europe by analysing how care is organised and identifying best practices
-
The project will conduct 18 ‘pathfinder’ studies to improve early detection, diagnosis, monitoring, and treatment of heart conditions, with a strong focus on prevention
-
The four key study areas will be AI & machine learning, digital health, point-of-care testing and technology & robotics.
-
The project’s vision is a future with significantly reduced burden of heart disease on patients, healthcare systems, and economies
Key takeaways:
-
Second second
-
Second second
-
Second second
Key takeaways:
Utrecht, Netherlands – 23 June 2025
The EuroHeartPath project, officially launched under the Horizon Europe Innovative Health Initiative Joint Undertaking (IHI-JU), brings together 35 leading academic, clinical, public health, industry, and societal partners from across Europe. With a significant €27 million budget spanning a five-year timeline, EuroHeartPath is set to radically transform cardiovascular care by mapping, comparing, and optimizing care pathways throughout the continuum of heart disease.
Despite significant advancements, cardiovascular disease (CVD) remains Europe’s leading cause of death and disability. EuroHeartPath addresses this critical challenge through an innovative pan-European approach, fostering cross-border learning, collaboration, and integration. The project comprises 18 pioneering pathfinder studies structured around four core technological areas: artificial intelligence (AI) and machine learning, digital health integration, point-of-care diagnostics, and advanced robotic technologies.
Examples of pathfinder studies include the PACEVALUE pathfinder, that addresses the significant gaps in the management of cardiovascular implantable electronic devices (CIEDs) for arrhythmias and heart failure; and the EXPLAIN pathfinder that leverages AI to enhance the interpretation of electrocardiograms (ECGs), aiming to overcome the limitations of current computerized ECG interpretations and expand on clinical utility.
Central to EuroHeartPath are patient-centeredness and equity, with dedicated efforts aimed at improving outcomes specifically for underserved groups, and promoting personalized, value-based healthcare.
Prof. Pim van der Harst, Coordinator and Head of Cardiology at UMC Utrecht, stated: “EuroHeartPath represents a unique chance to not only analyse cardiovascular care across Europe but fundamentally redesign it. This project leverages data, technology, and international collaboration to create a dynamic, learning healthcare system that can significantly enhance care quality, patient outcomes, and overall health system resilience.”
A unique pan-European and multi-sector collaboration
The EuroHeartPath consortium brings together diverse expertise from hospitals, academic institutions, technology innovators, policymakers, and patient advocacy groups. Through this unique collaboration, partners aim to bridge the gap between innovation and clinical practice, ensuring that breakthroughs quickly translate into practical, widespread benefits for European citizens at risk of or living with heart disease.
EUPHA is proud to be part of the EuroHeartPath consortium. We provide targeted support by contributing its public health expertise. Our role will involve supporting improvements in care delivery by sharing best practices across countries, helping to ensure patient data is used ethically and safely, and contributing to the planning of how the project’s results can be sustained and used in the long term.
Julian Hein (EUPHA’s Science & Project Manager) commented: “Participating in EuroHeartPath underscores our commitment to improving cardiovascular health across Europe. We bring our expertise from within the EUPHA Chronic Diseases section and EUPHA project management to this ambitious initiative, and we look forward to achieving significant advancements in cardiovascular care alongside our European partners.’”
About EuroHeartPath:
Funded by the Innovative Health Initiative Joint Undertaking (IHI-JU), EuroHeartPath unites prominent stakeholders including UMC Utrecht, Amsterdam UMC, London School of Economics and Political Science, Technische Universiteit Eindhoven, Deutsches Herzzentrum München, Insel Gruppe AG (University Hospital Bern), Servicio Madrileño de Salud (SERMAS), Assistance Publique Hôpitaux de Paris (APHP), RCF@ICPS, Charité – Universitätsmedizin Berlin, Universiteit Maastricht, Philips Medical Systems Nederland BV, Philips France Commercial, Medtronic Ibérica SA, Medtronic GmbH, AstraZeneca UK Limited, Boston Scientific Netherlands BV, IQVIA Solutions Belgium BV, Novo Nordisk A/S, Novartis Pharma BV, Amarin Pharmaceuticals Ireland Limited, Vintura BV, Zeesta Labs, Corbotics BV, Chateau Sante, Van Vliet Diagnostics BV, Cordys Analytics, Viduet Health B.V, Stichting Cardiologie Centra Nederland, Heart for Health ICT BV, Cito Diagnostics BV, Discovery XD One SRL, Stichting WONCA Europe, European Society of Cardiology (ESC), European Pathway Association (EPA), Outcomes’10 SL, European Public Health Association (EUPHA). The initiative spans multiple European countries, aiming to set new standards in cardiovascular care.
